Two preclinical findings offer complementary routes to improve checkpoint immunotherapy. MIT engineers reported polymer‑coated nanoparticles that deliver IL‑12 directly into ovarian tumors; in mouse models the IL‑12 plus checkpoint inhibitor combination eradicated metastatic lesions in over 80% of animals and generated durable immune memory. Separately, Dana‑Farber scientists mapped interferon‑gamma (IFNγ) signaling in tumor‑associated myeloid cells as a driver of resistance to PD‑1/PD‑L1 blockade in renal cell carcinoma, identifying myeloid IFNγ pathways as actionable targets to reverse immune suppression. Together the studies describe both a delivery platform to concentrate potent cytokines in the tumor microenvironment and a mechanistic route by which myeloid signaling blunts checkpoint efficacy—two intersecting approaches that could inform next‑generation combination strategies.